These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34932882)

  • 21. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
    Chen Z; Li G
    Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium-glucose co-transporter 2 inhibitors on weight change and cardiometabolic profiles in individuals with overweight or obesity and without diabetes: A meta-analysis.
    Wong J; Chan KY; Lo K
    Obes Rev; 2021 Dec; 22(12):e13336. PubMed ID: 34542222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials.
    Tang H; Zhang X; Zhang J; Li Y; Del Gobbo LC; Zhai S; Song Y
    Diabetologia; 2016 Dec; 59(12):2546-2551. PubMed ID: 27628105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
    Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
    Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
    Mazidi M; Rezaie P; Gao HK; Kengne AP
    J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28546454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.
    Tang H; Li D; Zhang J; Li Y; Wang T; Zhai S; Song Y
    Diabetes Obes Metab; 2017 Aug; 19(8):1106-1115. PubMed ID: 28240446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Pan R; Zhang Y; Wang R; Xu Y; Ji H; Zhao Y
    PLoS One; 2022; 17(12):e0279889. PubMed ID: 36584211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.
    Ruanpeng D; Ungprasert P; Sangtian J; Harindhanavudhi T
    Diabetes Metab Res Rev; 2017 Sep; 33(6):. PubMed ID: 28440590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
    Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
    Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium-glucose cotransporter-2 inhibitors in heart failure patients across the range of body mass index: a systematic review and meta-analysis of randomized controlled trials.
    Adamou A; Chlorogiannis DD; Kyriakoulis IG; Stamatiou I; Koukousaki D; Kardoutsos I; Sagris D; Doehner W; Ntaios G
    Intern Emerg Med; 2024 Mar; 19(2):565-573. PubMed ID: 38353880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling.
    Sokolov V; Yakovleva T; Chu L; Tang W; Greasley PJ; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
    CPT Pharmacometrics Syst Pharmacol; 2020 Apr; 9(4):222-229. PubMed ID: 32064793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short- and medium-term efficacy of sodium glucose cotransporter 2 (SGLT-2) inhibitors for the treatment of type 1 diabetes: systematic review and meta-analysis.
    Huang Y; Jiang Z; Wei Y
    Endokrynol Pol; 2020; 71(4):325-333. PubMed ID: 32901912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials.
    Teo YH; Yoong CSY; Syn NL; Teo YN; Cheong JYA; Lim YC; Lee CH; Yeo TC; Chai P; Wong RCC; Lin W; Sia CH
    Eur J Clin Pharmacol; 2021 Oct; 77(10):1453-1464. PubMed ID: 33942132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials.
    Dicembrini I; Tomberli B; Nreu B; Baldereschi GI; Fanelli F; Mannucci E; Monami M
    Diabetes Res Clin Pract; 2019 Jul; 153():138-144. PubMed ID: 31150722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials.
    Saad M; Mahmoud AN; Elgendy IY; Abuzaid A; Barakat AF; Elgendy AY; Al-Ani M; Mentias A; Nairooz R; Bavry AA; Mukherjee D
    Int J Cardiol; 2017 Feb; 228():352-358. PubMed ID: 27866027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.
    Li D; Wang T; Shen S; Fang Z; Dong Y; Tang H
    Diabetes Obes Metab; 2017 Mar; 19(3):348-355. PubMed ID: 27862830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Outcome studies on SGLT-2 inhibitors].
    Seufert J; Laubner K
    Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events.
    Aziri B; Begic E; Jankovic S; Mladenovic Z; Stanetic B; Kovacevic-Preradovic T; Iglica A; Mujakovic A
    ESC Heart Fail; 2023 Jun; 10(3):1499-1530. PubMed ID: 36967133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.